Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma

• Hauptverfasser: Veera Venkata Satyanarayana Reddy Karri (Verfasst von), Nagasamy Venkatesh Dhandapani (Verfasst von), Sai Sandeep Mannemala (Verfasst von), Kollipara Radhakrishna (Verfasst von), Shashank Mulukutla (Verfasst von), Dedeepya Sudunagunta (Verfasst von)
• Format: Buch
• Veröffentlicht: Universidade de São Paulo, 2017-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Lenalidomide (LND) is an anti-cancer drug and an effective derivative of thalidomide used for multiple myeloma therapy. Because of its poor solubility in water, LND is known to cause low oral bioavailability (below 33%), and as a direct consequence of this, the dosing frequency is extended...